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ADHERENCE THROUGH THE PROCESS OF AUDIT, LED BY JUNIOR DOC-
TORS
Gerard Walls *, David Curry, Hugh O'Kane. Regional Urology Unit, Belfast City
Hospital, Northern Ireland, UK.
Introduction: The authors intended to establish adherence to guidelines
regarding time to administration of intravesical chemotherapy post-
TURBT, in the Regional Urology Unit. EORTC recommends Mitomycin C
(MMC) instillation within 6 hours in eligible patients - this reduces
recurrence rates by 39%.
Methods: Prospective audit of time to administration in all eligible pa-
tients during a 3 month period. Results were discussed at departmental
level with a three tiered approach to improvement. Primarily, initiation of
in-theatre instillation (Mostaﬁd et al). Second, a training programme for
ward staff in handling cytotoxic agents. Finally, awareness of the problem
was raised to trainee urologists at the Regional Audit Meeting. A repeat
three month audit series was performed six months later. The latter two
processes had been implemented with plans for in-theatre administration
on-going.
Results: Initially, in 19 patients (40 eligible) the mean time to MMC
administration was 18.3hrs (2.3-28.2hrs). 15.7% patients received MMC
<6hrs. In the second series of 9 patients (13 eligible), the meantime to
MMC administration was 5.2hrs (1-17.25hrs), and 88.9% received MMC
<6hrs (none after 24hrs).
Conclusions: Improvement in MMC administration practice is seen
following simple interventions led by junior doctors. Through on-going
training, adjustment of systems and audit, we hope further improvements
can be seen.
0379: AN AUDIT OF UPPER RENAL TRACT UROTHELIAL BIOSPY: OUR
INITIAL EXPERIENCE OF BIGOPSY FORCEPS
Sotonye Tolofari *, Basharat Hussain, Wai-Man Chow. Pennine Acute
Hospitals NHS Trust, Manchester, UK.
Introduction: Biopsy is the gold standard for diagnosis of upper renal tract
malignancy. It's always an urologist's challenge to achieve a representative
sample for accurate diagnosis. Recent evidence suggests 3mm is the
minimal biopsy size required for adequate histopathological diagnosis. We
present an audit of our experiences with different biopsy devices.
Methods: 45 patients underwent ureteroscopic/ureterorenoscopic biopsy
of urothelial lesions. All biopsies were sent for analysis by a histopathol-
ogist with an expertise in urological pathology.
Results: 33 patients underwent urothelial biopsies using the following
devices; Piranha(29), reusable forceps(3) and Dormia basket(1). There
were 31 ureteric lesions and two pelvicalyceal lesions. Specimen sizes
ranged from <1mm (5), 1mm (14), 2mm (8) and 3mm (2). 8 patients
required a re-biopsy. Further immunohistochemical analysis (4) and re-
petitive reviews (4) were required for diagnostic conﬁrmation. 12 patients,
underwent biopsies of ureteric lesions (10) and pelvicalyceal lesions (2)
using BIGopsy forceps. All specimens were measured >3mm, ﬁrst time.
Unanimous, unequivocal histopathological diagnoses were achieved.
Conclusions: Few biopsy devices provide satisfactory, representative and
consistent samples for diagnosis. We experienced an unpredictable
outcome with a 25% re-biopsy rate with various devices, however with
BIGopsy forceps accurate histopathological diagnoses were achieved with
a signiﬁcant impact on the timely treatment for urothelial malignancies.
0401: HOW CLINICAL AUDIT HAS LED TO REDUCED RATES OF POST
TRUS BIOPSY SEPSIS IN OUR TRUST
Nicholas Gill *, Michael Onyema, Anne Dyas, Vincent Koo, Paul Rajjayabun.
Alexandra Hospital, Redditch, UK.
Introduction: We recently reported the ﬁndings of a regional audit which
identiﬁed rates of sepsis increasing to 1.8% following transrectal ultra-
sound guided prostate biopsies (TRUS). Following this audit I.V. Genta-
micin 160mg was introduced as additional prophylaxis for patients
undergoing TRUS biopsy. Our aim was to assess the impact of adding
Gentamicin to the TRUS antibiotic prophylaxis bundle since implementa-
tion in August 2013.
Methods: Analysis of all patients who underwent TRUS biopsy across our Trust
between August-December 2013 with minimum 1-month follow up. Our ﬁnd-
ings were compared against our previous audit data and published literature.Results: Therewere 246 TRUS biopsy procedures carried out across the Trust
following the introduction of our new antibiotic prophylaxis regime. Median
age of the population examined was 67 years (range 42-84). Only 1 patient
was admitted to Secondary care with signiﬁcant sepsis (0.4%), 3 patients had
positive urine cultures performed inPrimarycare but didnot require hospital
admission (1.2%). There were no ITU admissions or mortalities.
Conclusion: We conclude that the addition of I.V. Gentamicin has
dramatically reduced the incidence of signiﬁcant sepsis post-TRUS biopsy.
This is an example of howwe have utilised audit tomodify clinical practice
for the beneﬁt of our patients.
0403: PROGNOSIS FOLLOWING PERCUTANEOUS NEPHROSTOMY INSER-
TION FOR MALIGNANT OBSTRUCTIVE UROPATHY: ONE CENTRE'S EXPE-
RIENCE
Nicholas Gill *, Kevin Williams, Phil Holland, Chris Phillips, Fabio Conti,
K. Wong, L. Delaney, L. Moore, Paul Rajjayabun. Alexandra Hospital,
Redditch, UK.
Introduction: Traditionally long-term survival post-nephrostomy inser-
tion for obstruction secondary to malignant uropathy has been variable,
however, it is often seen as a manifestation of disease progression. Our aim
was to assess patterns of nephrostomy insertion for patients presenting
with malignant ureteric obstruction in the modern era.
Methods: We analysed the nephrostomy service provided by our depart-
ment from January 2011 to June 2013. We focused on the indication of
malignant obstructive uropathy with a minimum of 5 months follow up.
Each nephrostomy insertion was considered a separate event.
Results: A total of 138 nephrostomy procedureswere performed for ureteric
obstruction secondary to pelvic or abdominal malignancy (n¼138, 68%).
There were 46 (33%) female and 92 (67%) male patients. Median patient age
was 72.2 (range 42-91) years. Obstruction secondary to prostate cancer (34%)
and bladder cancer (34%)were themost frequent indication for intervention.
Median survival post-insertion was 73 (range 2-593) days with only 30% of
this patient group demonstrating long-term survival. A signiﬁcant group of
patients failed to survive for >30 days post-procedure (n¼19, 12%).
Conclusions: Nephrostomy insertion for malignant ureteric obstruction is
a hallmark of disease progression. Patients who undergo this invasive
procedure often have poor survival characteristics. Each should be coun-
selled carefully before undertaking nephrostomy insertion.
0519: A RETROSPECTIVE AUDIT OF POST TRUSS GUIDED PROSTATE BI-
OPSY SEPSIS IN A DISTRICT GENERAL HOSPITAL e HOW ADEQUATE IS
ANTIBIOTIC PROPHYLAXIS IN THE FACE OF RISING RESISTANCE?
Kathleen Sweeney, Fungai Dengu *, Ismail El-Mokadem, Steve Leung.
Department of Urology, Victoria Hospital Kirkcaldy, Kirkcaldy, Fife, UK.
Introduction: Recent evidence suggests a rising incidence of serious
infective complications following TRUSS biopsy associated with signiﬁcant
morbidity and mortality due to ﬂuoroquinolone resistance. This audit aims
to determine the incidence of post biopsy sepsis in our hospital.
Methods: We retrospectively reviewed data from a prospectively main-
tained database of patients who underwent TRUSS biopsy over a 12-month
period at our District General Hospital. All patients received the standard
protocol of Ciproﬂoxacin and Metronidazole. We identiﬁed patients pre-
senting with symptoms suggestive of sepsis up to 30 days post TRUSS
biopsy. We reviewed their case notes to identify the rates of bacteuria,
bacteraemia and hospital admissions.
Results: 319 patients were biopsied and 22 (6.9%) presented with symp-
toms suggestive of infective complications. 10 (3.1%) had organisms
cultured from urine specimens and none had a bacteraemia. Only 2 (0.6%)
were admitted to hospital with clinically signiﬁcant urosepsis, both
culturing ﬂuoroquinolone resistant E. Coli.
Conclusions: Although ﬂuoroquinolone resistance may be increasing and
urosepsis is a life-threatening complication associated with resistance; our
results show it is a rare complication in our unit. Therefore no change in
antibiotic prophylaxis is warranted at present. However re-auditing is
essential to identifying the reported emergence of clinically signiﬁcant
resistance.
0558: THE INCIDENCE OF UTI FOLLOWING FLEXIBLE CYSTOSCOPY:
SHOULD WE CHANGE OUR ANTIBIOTIC PRACTICE?
Luke McGuinness *, Sophie Christopher, Ciaran Lynch. Royal Liverpool and
Broadgreen University Hospitals, Liverpool, UK.
